COVALENT GROUP, INC. ENTERS INTO COMBINATION AGREEMENT

Covalent Group, Inc., a leader in the design and management of complex clinical trials and patient disease registries for the pharmaceutical, biotechnology and medical device industries, today announced that it has entered into a definitive combination agreement with Remedium Oy ("Remedium"), a privately-held, full-service clinical research organization ("CRO") based in Finland with offices in 8 countries throughout Scandinavia, Central Europe, and Eastern Europe.
Genetic Engineering News